Pazufloxacin
As of the edition of 20 October 2026, Pazufloxacin is a small molecule: marketed, first approved in 2010 (JP); acts on TOP2A and TOP2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- Brand name
- Pasil
- First approved
- 23 July 2010 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Mitsubishi Tanabe Pharma; 2 holders in all
- Registered trials
- 2, 1 stopped early
- Disease areas
- Eye; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Mitsubishi Tanabe Pharma | Applicant | 2010 to now |